Y-MABS THERAPEUTICS INC (YMAB) Stock Analyst Ratings
USA - NASDAQ:YMAB - US9842411095 - Common Stock
8.61 USD
+0.02 (+0.23%)
8.61 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 54% to YMAB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 8.2. This target is -4.75% below the current price.
YMAB was analyzed by 16 analysts. The buy percentage consensus is at 54. So analysts seem to be rather neutral about YMAB.
In the last month the buy percentage fell by 26 points. So the trust of analysts is decreasing.
YMAB was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-08-06 | Canaccord Genuity | Downgrade | Buy -> Hold |
| 2025-08-06 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2025-08-05 | Jones Trading | Downgrade | Buy -> Hold |
| 2025-05-29 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-14 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2025-05-14 | Truist Securities | Maintains | Buy -> Buy |
| 2025-03-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-05 | Truist Securities | Maintains | Buy -> Buy |
| 2025-03-05 | B of A Securities | Maintains | Neutral -> Neutral |
| 2025-03-05 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-11 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-05 | Brookline Capital | Initiate | Buy |
| 2024-11-18 | Oppenheimer | Initiate | Outperform |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-10 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-09-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-16 | Cantor Fitzgerald | Initiate | Overweight |
| 2024-08-13 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-08-13 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-08-13 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2024-08-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-11 | Jones Trading | Initiate | Buy |
| 2024-06-28 | Truist Securities | Initiate | Buy |
| 2024-05-13 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-06 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-03-04 | BMO Capital | Maintains | Outperform -> Outperform |
| 2024-03-04 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2024-02-20 | HC Wainwright & Co. | Maintains | Buy -> Buy |
Y-MABS THERAPEUTICS INC / YMAB FAQ
What is the price target for YMAB stock?
16 analysts have analysed YMAB and the average price target is 8.2 USD. This implies a price decrease of -4.75% is expected in the next year compared to the current price of 8.61.
Can you provide the consensus rating for Y-MABS THERAPEUTICS INC stock?
The consensus rating for Y-MABS THERAPEUTICS INC (YMAB) is 53.75 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
How many analysts cover Y-MABS THERAPEUTICS INC (YMAB) stock?
The number of analysts covering Y-MABS THERAPEUTICS INC (YMAB) is 16.